|
Melanoma Therapeutics Foundation - Board
of Directors
Melinda Ellis Evers
Managing Principal, Ellis Partners LLC
Interim Chair of the Board of Directors of the Melanoma Therapeutics Foundation
To honor her late father’s commitment to support efforts to accelerate the development of melanoma drug therapies, Melinda Ellis Evers has taken on the role of interim Chair of the Board of Directors.
Melinda Ellis Evers is a co-founder and Managing Principal of Ellis Partners, a boutique commercial real estate investment and development firm located in San Francisco. Prior to founding Ellis Partners in 1993, Melinda spent seven years in acquisitions and portfolio management with Grubb & Ellis Realty Advisers.
Melinda is a past President of the Bay Area Mortgage Association and past Board Member of the Foundation for San Francisco's Architectural Heritage and The Homeless Prenatal Program. She is currently active with The Urban Land Institute and the Lambda Alpha Land Economics Honor Society and serves as a Trustee of San Francisco Day School. She is a graduate of the University of California at Berkeley and the Stanford Graduate School of Business.
(return to top)
Nils Behnke, Ph.D.
Member of the Board of Directors of the Melanoma
Therapeutics Foundation
Mr. Behnke is a Partner in Bain & Company’s San
Francisco office. He is a member of the firm’s global
healthcare practice and an expert on biotechnology and specialty
pharmaceuticals. At Bain, Mr. Behnke serves biotech and pharma
clients on a variety of topics, including portfolio, licensing
and acquisition strategies and processes; R&D process optimization,
discovery and development services and capability sourcing;
product and franchise full potential (clinical development/positioning)
and commercial optimization (including re-launches, sales force
sizing/effectiveness, pricing strategies); and performance
improvement (revenue enhancement, cost reduction, organizational
and process optimization).
Besides pharma and biotech companies, Mr. Behnke has consulted
clients in other sectors of life sciences, including diagnostics,
discovery and development services, specialty drug providers
and biotech/pharma investors.
Mr. Behnke joined Bain in early 2004, after having spent four
years as CEO of a biopharmaceutical company focused on oncology.
In this capacity, he managed the product development of a monoclonal
antibody through phase I/II as well as the outlicensing of
the antibody to a pharma partner for phase III development.
Mr. Behnke has four years of prior consulting experience as
an Engagement Manager with McKinsey’s Pharmaceutical
and Medical Products Practice.
He holds a Ph.D. magna cum laude and an M.A. (ranked first)
from the University of Cologne in Germany.
(return to top)
Steve Ellis
Member of the Board of Directors of the Melanoma Therapeutics Foundation
Steve Ellis is the Worldwide Managing Director of Bain & Company. He joined Bain in 1993 from a Silicon Valley strategy consulting firm which he co-founded in 1989.
While at Bain, Mr. Ellis has been a leader in the firm's worldwide technology and telecommunications practice and the firm's Industry leading Private Equity Group. He has worked in a wide range of industries including, telecommunications, computer hardware and software, networking, financial services, information services, energy services, private equity and real estate. He has led engagements addressing business and corporate strategy, sales and marketing effectiveness, operational improvement, acquisition valuation, merger integration and change management.
Prior to his election as Worldwide Managing Director in 2005, Mr. Ellis served as office head of Bain's San Francisco and Palo Alto offices. He also serves as a general partner in the firm's Venture Capital Fund.
Mr. Ellis received a BA in economics and history, with honors, from the University of California at Berkeley. He earned an MBA from the Stanford Graduate School of Business.
(return to top)
Frank
McCormick, Ph.D., F.R.S.
Member of the Board of Directors and Chairman of the Scientific
Advisory Board of the Melanoma Therapeutics Foundation
Dr. McCormick is the Director of the University of California,
San Francisco (UCSF) Comprehensive Cancer Center, designated
by the National Cancer Institute (NCI, part of the National
Institutes of Health) and Cancer Research Institute, a multidisciplinary
research and clinical care organization that is one of the
largest matrix cancer centers in the Western United States.
A native of Cambridge, England, Dr. McCormick received his
B.Sc. in biochemistry from the University of Birmingham (1972)
and his Ph.D. in biochemistry from the University of Cambridge
(1975). Postdoctoral fellowships were held in the U.S. at the
State University of New York at Stony Brook and in London at
the Imperial Cancer Research Fund. He has been a Fellow of
the Royal Society since 1996.
Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related
work with several Bay Area biotechnology firms, including positions
with Cetus Corporation (Director of Molecular Biology, 1981-90;
Vice President of Research, 1990-91) and Chiron Corporation,
where he was Vice President of Research from 1991-92. In 1992
he founded Onyx Pharmaceuticals and served as its Chief Scientific
Officer until 1996.
Dr. McCormick's current research interests center on the fundamental
differences between normal and cancer cells that can allow
the development of novel therapeutic strategies. In addition
to his position as director of the UCSF Cancer Center, Frank
McCormick holds the David A. Wood Distinguished Professorship
of Tumor Biology and Cancer Research in UCSF's Department of
Microbiology and Immunology. Dr. McCormick is the author of
more than 243 scientific publications.
|
